Comparative efficacy and safety of 8 GLP-1RAs in patients with type 2 diabetes: A network meta-analysis

Systematic review (total 11,126 patients) found that all GLP-1 receptor agonists were more efficacious than placebo in patients with type 2 diabetes for efficacy, except albiglutide. Differences in safety profiles between agents were mostly not significant.

Diabetes Research and Clinical Practice